BMP1新纯合变异致罕见成骨不全表型
本文报告一名7岁男性携带BMP1基因新纯合错义变异(c.C505T; p.Arg169Cys),表现为多次双侧胫骨骨折、多发椎体压缩骨折及骨密度增高,并综述BMP1相关常染色体隐性成骨不全的临床特征与双膦酸盐治疗证据。
要点
- BMP1相关AR OI可表现为骨密度正常或反常增高,骨折风险与BMD相关性差。
- 双膦酸盐可能减少再发骨折并缓解症状,但证据有限且管理复杂。
- HR-pQCT评估骨微结构与质量可能辅助双膦酸盐治疗决策与监测。
核心结论
- BMP1相关AR OI患者骨密度可正常或反常增高,使BMD与骨折风险关联困难,双膦酸盐疗效证据有限。
研究设计与样本
- 病例报告:一名7岁男性,自2.5岁起轻微创伤后发生5次双侧胫骨骨折,伴语言和运动发育迟缓。
主要发现
- 6岁时跌倒后严重背痛,发现弥漫性脊柱骨量减少及T9、L1、L3、L5多发椎体压缩骨折。
- 全髋BMD校正Z-score为1.76,股骨颈BMD校正Z-score为2.67,腰椎BMD因椎体压缩骨折无法评估。
- 基因分析发现BMP1第4外显子纯合错义变异c.C505T(p.Arg169Cys)。
关键数值与推荐
- BMP1相关AR OI患者可表现为骨密度正常或反常增高,BMD与骨折风险相关性差。
- 双膦酸盐可能有助于减少再发骨折并提供症状缓解,但证据有限。
- HR-pQCT评估骨微结构和质量可能辅助双膦酸盐治疗决策及后续监测。
临床怎么用
- 对BMP1相关AR OI患者,不应仅依赖BMD评估骨折风险,需结合临床和影像学。
- 双膦酸盐治疗需个体化,可考虑HR-pQCT评估骨微结构辅助决策和监测。
局限性
- 本文为单例病例报告,证据有限,无法确立双膦酸盐在该罕见OI中的疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Osteogenesis imperfecta (OI) is characterized by bone fragility and increased fracture susceptibility. BMP1 variants have been reported in the rare OI type XIII, specifically referred to herein as BMP1-associated autosomal recessive (AR) OI. We report the clinical presentation and diagnostic evaluation of a patient found to have a novel homozygous variant in BMP1. We also provide an overview of reported BMP1 variants to date, with discussion focusing on the use of bisphosphonate therapy in these patients. A 7-year-old male with speech and motor delay sustained five bilateral tibial fractures with minimal trauma since age 2.5 years. At age 6, he developed severe back pain after a fall. Diffuse spinal osteopenia and multiple vertebral compression fractures (VCF) at T9, L1, L3, and L5 were identified. Total hip BMD was generous (adjusted Z-score* = 1.76), and femoral neck BMD was high (adjusted Z-score* = 2.67). VCFs precluded assessment of lumbar spine BMD. Genetic analysis identified a homozygous missense variant in exon 4 of BMP1 (c.C505T; p.Arg169Cys). Unlike most forms of OI, patients with BMP1-associated AR OI may have normal or paradoxically increased BMD, making BMD and fracture risk correlation difficult. While bisphosphonates (BP) may help reduce recurrent fractures and provide symptomatic relief, the broad phenotypic spectrum and underlying bone pathology, often in the setting of increased BMD, complicate management. HR-pQCT assessment of bone microarchitecture and quality may aid in the decision of BP therapy and subsequent monitoring. Evidence is limited with respect to the effectiveness of BP in this rare form of OI. *Z-score was adjusted for height Z-score.
引用
- Choksi IN, Cox A, Robinson C, et al. Novel homozygous variant in BMP1 associated with a rare osteogenesis imperfecta phenotype. Osteoporos Int. 2021. PMID: 33624138. doi:10.1007/s00198-021-05838-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。